Scholarlink

<p>The clotting characteristics of autologous whole blood clots for chronic wound management in patients on anticoagulant therapy are not well defined. An exploratory ex vivo study was performed using the ActiGraft autologous whole blood clot (RedDress Ltd, Haifa, Israel) in patients receiving oral anticoagulant therapy. Twenty-five participants were eligible for inclusion and stratified into three age-matched cohorts: vitamin K antagonist-warfarin (<i>n</i> = 9), factor Xa inhibitor- rivaroxaban (<i>n</i> = 6), and controls not receiving anticoagulation (<i>n</i> = 10). The primary endpoint was clot formation time. Clot formation time was defined as the time point at which no fluid movement was observed. In the study population (median [interquartile range] age 47 [42–52] years), the mean clot formation time was 10.5 ± 2.6&#xa0;min (reference:8–12&#xa0;min). Mean clot formation time was significantly different across groups (<i>p</i> &lt; 0.001). Compared with controls (8.4 ± 1.2&#xa0;min), clot formation time was significantly prolonged in both the warfarin group (11.3 ± 2.3&#xa0;min; <i>p</i> &lt; 0.002) and the rivaroxaban group (12.7 ± 2.4&#xa0;min; <i>p</i> &lt; 0.001), with no significant difference between anticoagulant groups (<i>p</i> = 0.297). Nonetheless, complete, stable clots were consistently formed within the expected time frame in all samples across all groups. This illustrates the feasibility of ActiGraft autologous whole blood clot in patients receiving therapeutic anticoagulation. Further studies are indicated in patients with chronic wounds to assess broader safety and efficacy.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autologous whole blood clot formation with actigraft in patients receiving oral anticoagulant therapy: an ex vivo feasibility study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月24日

查看全文
  • Barry Frank Jacobson,
  • Elise Schapkaitz,
  • Melanie Mc Cree

摘要

The clotting characteristics of autologous whole blood clots for chronic wound management in patients on anticoagulant therapy are not well defined. An exploratory ex vivo study was performed using the ActiGraft autologous whole blood clot (RedDress Ltd, Haifa, Israel) in patients receiving oral anticoagulant therapy. Twenty-five participants were eligible for inclusion and stratified into three age-matched cohorts: vitamin K antagonist-warfarin (n = 9), factor Xa inhibitor- rivaroxaban (n = 6), and controls not receiving anticoagulation (n = 10). The primary endpoint was clot formation time. Clot formation time was defined as the time point at which no fluid movement was observed. In the study population (median [interquartile range] age 47 [42–52] years), the mean clot formation time was 10.5 ± 2.6 min (reference:8–12 min). Mean clot formation time was significantly different across groups (p < 0.001). Compared with controls (8.4 ± 1.2 min), clot formation time was significantly prolonged in both the warfarin group (11.3 ± 2.3 min; p < 0.002) and the rivaroxaban group (12.7 ± 2.4 min; p < 0.001), with no significant difference between anticoagulant groups (p = 0.297). Nonetheless, complete, stable clots were consistently formed within the expected time frame in all samples across all groups. This illustrates the feasibility of ActiGraft autologous whole blood clot in patients receiving therapeutic anticoagulation. Further studies are indicated in patients with chronic wounds to assess broader safety and efficacy.

Graphical Abstract